PEG-IL-10 Conjugate Serum Half-Life Extension
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The short serum half-life of interleukin-10 (IL-10) limits its utility in cancer treatment, as it requires frequent administration and has a limited duration of action, which can impact its effectiveness in modulating immune responses against tumors.
Innovation Solution
Development of pegylated IL-10 (PEG-IL-10) with a longer serum half-life, using linkers like SC-PEG-12K or methoxy-PEG-aldehyde, which increases tumor killing activity by enhancing CD8+ T cell infiltration and expression of inflammatory cytokines, thereby inhibiting tumor growth.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If non-pegylated IL-10 is used for cancer treatment, then immune response modulation is achieved, but serum half-life is short (2-6 hours) requiring frequent administration
Solution Approach 1:
The patent applies PEGylation technology by covalently attaching polyethylene glycol chains to the IL-10 cytokine molecule, creating a composite PEG-IL-10 conjugate. This chemical modification extends the serum half-life of IL-10 from 2-6 hours to over 24 hours while maintaining its immunomodulatory activity, thereby resolving the contradiction between duration of action and treatment effectiveness
Solution Approach 2:
The patent modifies the physical and chemical parameters of IL-10 through PEGylation, specifically changing its molecular weight, hydrodynamic radius, and serum protein binding characteristics. These parameter changes result in extended circulation half-life and reduced clearance rate, enabling less frequent administration while maintaining therapeutic efficacy
2Reliability
If non-pegylated IL-10 is administered frequently to maintain effectiveness, then immune response is sustained, but treatment complexity and patient burden increase
Solution Approach 1:
By creating the PEG-IL-10 composite conjugate, the patent achieves sustained immune response modulation with single or infrequent administrations. The PEG moiety acts as a pharmacokinetic enhancer that maintains stable drug levels in circulation, eliminating the need for frequent dosing while ensuring reliable immune response
Solution Approach 2:
The PEGylation modification enables continuous therapeutic action of IL-10 by preventing rapid renal clearance and proteolytic degradation. The extended half-life ensures continuous presence of active cytokine at the tumor site, maintaining reliable immune response without requiring repeated administrations
3Duration of action of moving object
If PEG-IL-10 is used to extend half-life, then serum persistence is improved, but tumor killing activity is enhanced beyond expected levels
Solution Approach 1:
The PEG-IL-10 conjugate not only extends half-life but also enhances tumor killing activity through multiple mechanisms: increased CD8+ T cell infiltration into tumor tissue, upregulation of inflammatory cytokines (IFNγ, IL-6, IL-12), and activation of macrophages. This synergistic effect transforms the composite material into a more potent anti-tumor agent than simple half-life extension would predict
Solution Approach 2:
The PEG linker acts as an intermediary that not only provides pharmacokinetic benefits but also facilitates enhanced interaction between IL-10 and immune cells. The modified cytokine structure improves binding affinity to IL-10 receptors on immune cells, amplifying the immunostimulatory effect and enhancing tumor cell lysis
Data Source
AI summary
Provided are methods of treatment for tumors. In particular, methods are provided for use of a chemically modified IL-10 to treat tumors.